These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 23095282)

  • 41. Clinical improvement in rheumatoid arthritis is associated with healthier microvascular function in patients who respond to antirheumatic therapy.
    Galarraga B; Belch JJ; Pullar T; Ogston S; Khan F
    J Rheumatol; 2010 Mar; 37(3):521-8. PubMed ID: 20080919
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Peripheral blood lymphocytes from patients with rheumatoid arthritis are differentially sensitive to apoptosis induced by anti-tumour necrosis factor-alpha therapy.
    Coury F; Ferraro-Peyret C; Le Cam S; Guerin S; Tebib J; Sibilia J; Bienvenu J; Fabien N
    Clin Exp Rheumatol; 2008; 26(2):234-9. PubMed ID: 18565243
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Etanercept increases tumor necrosis factor-alpha level but not sFas level in patients with rheumatoid arthritis.
    Kotyla P; Jankiewicz-Ziobro K; Owczarek A; Kucharz EJ
    Isr Med Assoc J; 2015 Jan; 17(1):14-8. PubMed ID: 25739170
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-alpha blocking agents.
    Halvorsen EH; Haavardsholm EA; Pollmann S; Boonen A; van der Heijde D; Kvien TK; Molberg Ø
    Ann Rheum Dis; 2009 Feb; 68(2):249-52. PubMed ID: 18723564
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-α-inhibitor.
    Hjeltnes G; Hollan I; Førre O; Wiik A; Lyberg T; Mikkelsen K; Agewall S
    Clin Exp Rheumatol; 2013; 31(3):415-21. PubMed ID: 23465067
    [TBL] [Abstract][Full Text] [Related]  

  • 46. TNFα antagonist therapy does not increase the Epstein-Barr virus burden in patients with rheumatoid arthritis or ankylosing spondylitis.
    Couderc M; Payet S; Henquell C; Dubost JJ; Soubrier M
    Joint Bone Spine; 2010 Oct; 77(5):414-7. PubMed ID: 20542718
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.
    Harrison MJ; Dixon WG; Watson KD; King Y; Groves R; Hyrich KL; Symmons DP; ;
    Ann Rheum Dis; 2009 Feb; 68(2):209-15. PubMed ID: 18385277
    [TBL] [Abstract][Full Text] [Related]  

  • 48. No significant change in arterial stiffness in RA after 6 months and 1 year of rituximab treatment.
    Mathieu S; Pereira B; Dubost JJ; Lusson JR; Soubrier M
    Rheumatology (Oxford); 2012 Jun; 51(6):1107-11. PubMed ID: 22328565
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Do biologic therapies reduce aortic inflammation in rheumatoid arthritis patients?
    Trang DAMT; Okamura K; Suto T; Sakane H; Yonemoto Y; Nakajima T; Tsushima Y; Chikuda H
    Arthritis Res Ther; 2021 Aug; 23(1):206. PubMed ID: 34344436
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
    Gonnet-Gracia C; Barnetche T; Richez C; Blanco P; Dehais J; Schaeverbeke T
    Clin Exp Rheumatol; 2008; 26(3):401-7. PubMed ID: 18578960
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks.
    Anolik JH; Ravikumar R; Barnard J; Owen T; Almudevar A; Milner EC; Miller CH; Dutcher PO; Hadley JA; Sanz I
    J Immunol; 2008 Jan; 180(2):688-92. PubMed ID: 18178805
    [TBL] [Abstract][Full Text] [Related]  

  • 52. TNF inhibitors induce discoid fibrosis in the sublining layers of the synovium with degeneration of synoviocytes in rheumatoid arthritis.
    Hirohata S; Tomita T; Yoshikawa H; Kyogoku M
    Rheumatol Int; 2013 Oct; 33(10):2473-81. PubMed ID: 23575549
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Etanercept decreases synovial expression of tumour necrosis factor-α and lymphotoxin-α in rheumatoid arthritis.
    Neregård P; Krishnamurthy A; Revu S; Engström M; af Klint E; Catrina AI
    Scand J Rheumatol; 2014; 43(2):85-90. PubMed ID: 24313444
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis.
    Kastbom A; Bratt J; Ernestam S; Lampa J; Padyukov L; Söderkvist P; Skogh T
    Arthritis Rheum; 2007 Feb; 56(2):448-52. PubMed ID: 17265480
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of the clinical characteristics of vasculitis occurring during anti-tumor necrosis factor treatment or not in rheumatoid arthritis patients. A systematic review of 2707 patients, 18 vasculitis.
    Guignard S; Gossec L; Bandinelli F; Dougados M
    Clin Exp Rheumatol; 2008; 26(3 Suppl 49):S23-9. PubMed ID: 18799049
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
    Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
    Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of total arthroplasty combined with anti-tumor necrosis factor agents in attenuating systemic disease activity in patients with rheumatoid arthritis.
    Hayashi M; Kojima T; Funahashi K; Kato D; Matsubara H; Shioura T; Kanayama Y; Hirano Y; Ishiguro N
    Mod Rheumatol; 2012 Jun; 22(3):363-9. PubMed ID: 21979824
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.
    Yun H; Xie F; Delzell E; Chen L; Levitan EB; Lewis JD; Saag KG; Beukelman T; Winthrop K; Baddley JW; Curtis JR
    Ann Rheum Dis; 2015 Jun; 74(6):1065-71. PubMed ID: 24608404
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity.
    Caramaschi P; Biasi D; Colombatti M; Pieropan S; Martinelli N; Carletto A; Volpe A; Pacor LM; Bambara LM
    Rheumatol Int; 2006 Jan; 26(3):209-14. PubMed ID: 15627197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.